Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsAmeriHealth Select Drug Program Coverage Policy Up…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAmeriHealthPolicy N/A

    Select Drug Program Formulary (pharmacy benefit) — Coverage Criteria

    Customize your policy alerts

    Sign up for all AmeriHealth policy alerts

    Know when AmeriHealth releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines the AmeriHealth Select Drug Program formulary structure, safety edits, prior authorization and quantity limits, and ACA preventive medication coverage affecting members and providers under the pharmacy benefit.

    Policy Summary
    PayerAmeriHealth
    PolicySelect Drug Program Formulary (pharmacy benefit) — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJan 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization before submitting claims for drugs flagged 'PA' or for claims exceeding dollar or dose thresholds.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    >$10kclaim dollar PA threshold
    90 MME/dayopioid MME limit
    60–72 mg/daystimulant dose thresholds
    75%refill policy
    SP notedspecialty drugs

    Coverage & Utilization Management Criteria

    Coverage with utilization management criteria

    Coverage and utilization management are governed by prior authorization and safety edits; drugs are covered when criteria below are met.

    General prior authorization and safety edits: Provider must obtain prior authorization for drugs that require it; claims with total cost at or above the dollar limit threshold require prior authorization; prior authorization requests must include complete supporting clinical information and may be time-limited.See claim dollar threshold (>= $10,000) and PA documentation requirements

    Based on policy requirements for PA, claim dollar limits, and documentation; prior authorization review may take up to two business days after complete information is received.

    Quantity and day supply limits: Quantity limits (quantity over time, maximum daily dose, refill-too-soon at 75% utilization) and day-supply limits apply; providers must submit prior authorization for overrides or quantities beyond limits.Examples provided in quantity limits (e.g., Nuvaring = 1 per 28 days; zolpidem = 1/day)
    Policy Summary
    PayerAmeriHealth
    PolicySelect Drug Program Formulary (pharmacy benefit) — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJan 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization before submitting claims for drugs flagged 'PA' or for claims exceeding dollar or dose thresholds.
    SourceLink
    On This Page
    Coverage & Utilization Management CriteriaCoding Thresholds and LimitsProvider Requirements, Prior Authorization & SubmissionStep Therapy & Management CodesQuantity and Day-Supply LimitsSpecialty Pharmacy and Site-of-CarePolicy BackgroundDefinitions & Legend

    Quantity limits are intended to ensure safe and appropriate utilization; override requests may be time-limited.

    Opioid safety edit: Prior authorization is required if the member's total daily opioid dose exceeds the Morphine Milligram Equivalent (MME) limit.>90 MME/day

    MME limit and requirement for PA are specified in policy.

    Cumulative stimulant safety edit: Stimulant claims that exceed high cumulative daily dose limits calculated by active ingredient require prior authorization; per-ingredient thresholds are provided for amphetamine and methylphenidate classes.See per-ingredient high cumulative daily dose thresholds (e.g., amphetamine = 60 mg/day; lisdexamfetamine = 70 mg/day; methylphenidate = 72 mg/day)

    Cumulative stimulant limit calculates total daily stimulant dose by active ingredient to mitigate cardiac and neuropsychiatric risks.

    Stimulant cumulative dose coverage

    Covered when ALL of the following are met

    Cumulative dose within limits or PA obtained: Claims for central nervous system stimulants must have a cumulative daily dose by active ingredient at or below the policy's specified high cumulative daily dose thresholds; if the calculated cumulative dose exceeds the listed per-ingredient threshold, prior authorization must be obtained for coverage.Per-ingredient thresholds (examples): amphetamine = 60 mg/day; amphetamine-dextroamphetamine = 60 mg/day; dextroamphetamine = 60 mg/day; lisdexamfetamine = 70 mg/day; dexmethylphenidate = 40 mg/day; methylphenidate = 72 mg/day; serdexmethylphenidate = 52.3 mg/day

    Cumulative stimulant limit is calculated by active ingredient and is a safety measure due to risks of cardiac adverse events and psychosis with high-dose stimulants.

    Drugs Requiring Prior Authorization

    Covered when prior authorization is obtained for listed drugs and formulary requirement codes met

    PA for listed drugs: Prior authorization must be obtained for the specific drugs and all formulations listed in this section before coverage will be approved.See formulary entries and requirement codes (PA, QL, 5DS, MME, etc.)

    List in the source is extensive; policy notes that PA applies to all formulations and that some brand prenatal vitamins and certain diabetic test strips also require PA; compound products >= $75 and claims >= $10,000 also trigger PA.

    Inclusion of a medication on the formulary does not by itself guarantee coverage for every member. Benefits vary by group, and not all cost-share tiers or incentives (for example, the Low-Cost Generic incentive) are available on every plan. Drugs not listed in the formulary guide may still be covered but will be assigned the appropriate cost-share tier per the member’s benefit booklet; likewise, covered brand drugs not listed in the guide are generally treated at the Non-preferred level of cost-sharing.

    Tier exception requests are subject to limits. Providers must generally document trial of, or contraindication to, at least three formulary alternatives when applicable. Drugs on the Generic, Preferred Brand, and Specialty tiers are not eligible for tier exceptions, and some plans do not permit tier exceptions — refer to the member benefit booklet for plan-specific availability.

    To request a tier exception, complete the formulary exception request form with supporting clinical detail and fax it to 1-888-671-5285. If approved, the drug will pay at the appropriate preferred brand or generic level of cost-sharing; if denied, the member and provider will receive a denial letter with appeals information.

    Coding Thresholds and Limits

    inv-06: Amphetamine high cumulative daily dose — 60mg/day
    Threshold60 mg/day
    Applies toAmphetamine products (e.g., Adzenys ER ODT, Dyanavel, Evekeo ODT)
    Action when exceededPrior authorization required
    inv-07: Amphetamine-Dextroamphetamine high cumulative daily dose — 60mg/day
    Threshold60 mg/day
    Applies toAmphetamine‑Dextroamphetamine products (e.g., Adderall IR/XR, Mydayis)
    Action when exceededPrior authorization required
    inv-08: Dextroamphetamine high cumulative daily dose — 60mg/day
    Threshold60 mg/day
    Applies toDextroamphetamine products (e.g., Dexedrine, Zenzedi, ProCentra, Xelstrym)
    Action when exceededPrior authorization required
    inv-09: Lisdexamfetamine high cumulative daily dose — 70mg/day
    Threshold70 mg/day
    Applies toLisdexamfetamine products (e.g., Vyvanse)
    Action when exceededPrior authorization required
    inv-10: Dexmethylphenidate high cumulative daily dose — 40mg/day
    Threshold40 mg/day
    Applies toDexmethylphenidate products (e.g., Focalin IR/XR)
    Action when exceededPrior authorization required
    inv-11: Methylphenidate high cumulative daily dose — 72mg/day
    Threshold72 mg/day
    Applies toMethylphenidate products (e.g., Ritalin IR/LA, Concerta, Quillivant XR, Jornay PM, Adhansia XR)
    Action when exceededPrior authorization required
    inv-12: Serdexmethylphenidate high cumulative daily dose — 52.3mg/day
    Threshold52.3 mg/day
    Applies toSerdexmethylphenidate products (e.g., Azstarys)
    Action when exceededPrior authorization required
    inv-13: Opioid MME limit — 90 MME/day
    Threshold90 MME/day
    Applies toOpioid products (MME calculated across opioid agents)
    Action when exceededPrior authorization required
    inv-14: Amphetamine high cumulative daily dose (dup) — 60mg/day
    Threshold60 mg/day
    Applies toAmphetamine products (duplicate entry)
    Action when exceededPrior authorization required
    inv-15: Amphetamine-Dextroamphetamine high cumulative daily dose (dup) — 60mg/day
    Threshold60 mg/day
    Applies toAmphetamine‑Dextroamphetamine products (duplicate entry)
    Action when exceededPrior authorization required
    inv-16: Dextroamphetamine high cumulative daily dose (dup) — 60mg/day
    Threshold60 mg/day
    Applies toDextroamphetamine products (duplicate entry)
    Action when exceededPrior authorization required
    inv-17: Lisdexamfetamine high cumulative daily dose (dup) — 70mg/day
    Threshold70 mg/day
    Applies toLisdexamfetamine products (duplicate entry)
    Action when exceededPrior authorization required
    inv-18: Methamphetamine high cumulative daily dose — 60mg/day
    Threshold60 mg/day
    Applies toMethamphetamine products (e.g., Desoxyn)
    Action when exceededPrior authorization required
    inv-19: Dexmethylphenidate high cumulative daily dose (dup) — 40mg/day
    Threshold40 mg/day
    Applies toDexmethylphenidate products (duplicate entry)
    Action when exceededPrior authorization required
    inv-20: Methylphenidate high cumulative daily dose (dup) — 72mg/day
    Threshold72 mg/day
    Applies toMethylphenidate products (duplicate entry)
    Action when exceededPrior authorization required
    inv-21: Serdexmethylphenidate high cumulative daily dose (dup) — 52.3mg/day
    Threshold52.3 mg/day
    Applies toSerdexmethylphenidate products (duplicate entry)
    Action when exceededPrior authorization required
    inv-22: Claim dollar limit threshold — >= $10,000 per claim
    Threshold>= $10,000 per claim
    Applies toAny prescription claim exceeding the dollar limit threshold
    Action when exceededPrior authorization required; claim may be denied without PA
    inv-23: Compound product cost threshold — >= $75 per prescription
    Threshold>= $75 per prescription (compound products)
    Applies toCompound products with total cost equal to or greater than $75
    Action when exceededPrior authorization required; may be denied without PA
    inv-24: Quantity/Limit indicators — examples QL, 5DS, MME
    ExamplesQL (Quantity Limits), 5DS (Day Supply Limit), MME (Morphine Milligram Equivalent)
    UsageFlags shown in drug entries indicate applicable utilization controls (e.g., QL, 5DS, MME)
    ReferenceSee formulary legend for full abbreviation list

    Provider Requirements, Prior Authorization & Submission

    Prior Authorization

    Prior Authorization Requirement

    Prior Authorization Required — scope and overview. AmeriHealth requires prior authorization (PA) for many prescription drugs to confirm medical necessity and clinical appropriateness. PA applies to specific drugs and to certain claim and product thresholds; claims submitted without an approved PA may be denied at point-of-sale or at adjudication. Clinical pharmacists and medical directors review PA requests using criteria approved by the Pharmacy & Therapeutics Committee.

    • PA applies to many listed drugs across the formulary — drugs marked with the requirement code "PA" require authorization before coverage.
    • PA applies to all formulations of listed drugs (tablet, capsule, oral suspensions, injectables, topical, etc.) where noted.
    • High-dollar claim threshold: prescription claims exceeding $10,000 per claim require prior authorization.
    • Compound products with total cost >= $75 per prescription require prior authorization.
    • Some drugs also include plan-specific indicators (R = Requires Rider) or specialty flags — check requirement codes.
    • Quantity/day-supply/MME enforcement: when quantity limits, day-supply (5DS), or Morphine Milligram Equivalent (MME) limits apply, claims exceeding limits require supporting documentation and may be denied or reduced.
    • PA approvals may be time-limited (e.g., 6–12 months); renewal requires a new PA submission when the authorization expires.
    Documentation Required

    Prior Authorization Documentation & Supporting Evidence

    Documentation required for PA requests. Provide complete clinical information to support medical necessity, including diagnosis, previous therapies and outcomes, rationale for the requested agent/dose, and any relevant lab or monitoring data. Incomplete submissions may delay the decision or result in denial. When requesting overrides for quantity limits or MME/5DS flags, include documentation justifying the need (e.g., dosing records, specialty clinic notes).

    • When limits apply (QL, 5DS, MME), include supporting documentation for overrides.
    • For opioid PA requests exceeding 90 MME/day, include opioid therapy history and justification.
    • For stimulant cumulative limit overrides, provide active-ingredient dosing history and clinical rationale.
    • Some PA approvals require periodic reauthorization; include documentation for continuation requests.
    Billing Rule

    How to Submit Prior Authorization & Formulary Exception Requests

    How to submit PA and formulary exception requests. Use the electronic prior authorization (ePA) platform (e.g., SureScripts™) for faster, sometimes real-time, decisions. Alternatively, submit a completed prior authorization fax form or a letter of medical necessity to the pharmacy benefit manager. Formulary tier exception requests follow a separate process and require demonstration of trials or contraindications to formulary alternatives.

    • ePA (SureScripts™) is supported and may provide real-time approvals.
    • Fax prior authorization forms or letters of medical necessity to: 1-888-671-5285. Forms available: https://www.amerihealth.com/providers/pharmacy_information/index.html
    • Tier exception requests: typically require trial of, or contraindication to, at least three formulary alternatives when applicable; some tiers/plan types are not eligible for tier exceptions — check the member benefit booklet.
    • If PA is approved, provider will be notified via fax/phone and the claim system will be coded with the approval; if denied, appeals instructions are provided in the denial letter.
    Note

    Requirement Codes, Legend & Utilization Management

    Utilization management procedures and requirement codes. The formulary includes management codes (PA, QL, 5DS, MME, LDD, AL, R, SP, +) that indicate required actions or limits. Providers must review these codes when prescribing; PA and other limits are enforced at adjudication.

    • Legend highlights: PA = Prior Authorization; QL = Quantity Limits; 5DS = Day Supply Limit; MME = Morphine Milligram Equivalent; LDD = Limited Distribution Drug; AL = Age Limit; R = Requires Rider; + = Claim Dollar Limit.
    • Drugs flagged with PA require an approved authorization before coverage; drugs flagged with QL/5DS/MME may be denied or reduced if limits are exceeded.
    • Some entries also include plan-specific 'R' (Requires Rider) indicators — verify member benefit/rider eligibility before prescribing.
    Prior Authorization

    Authorization Scope — applicable products and examples

    Authorization scope and specific examples. Prior authorization applies to numerous specific listed agents across the formulary — including many brand and generic products, specialty agents, topical agents, prenatal vitamins, diabetic test strips (except specified brands), high-cost biologics, and other listed drugs. PA frequently applies to all formulations of the listed agents.

    • All brand prenatal vitamins require prior authorization.
    • All diabetic test strips require prior authorization except for Contour®.
    • Compound prescriptions with total cost >= $75 require PA.
    • Many specialty products (e.g., Epidiolex Soln, Emgality Prefilled Pen/Auto-Injector) are marked PA and may also have QL/5DS/MME flags.
    • Numerous topical and dermatology agents are subject to PA and QL (see formulary listing).
    Denial Risk

    High-dollar Claims, MME, Quantity & Stimulant Limits — Provider Actions

    Provider actions for high-cost and limit-exceeding claims. Before submitting prescriptions or dispensing, check formulary requirement codes and submit PA for high-dollar claims or when limits are exceeded. Failure to obtain PA will likely result in claim denial and member financial liability.

    • Claims exceeding $10,000 per claim require prior authorization.
    • Claims for opioids exceeding 90 MME/day require prior authorization.
    • Stimulant claims exceeding cumulative active-ingredient dose limits (per formulary) require prior authorization and may be denied at point-of-sale.
    • When quantity/day-supply limits are exceeded, submit PA with supporting clinical rationale to request an override.

    Step Therapy & Management Codes

    Utilization management toolHow it's used / examples
    Prior Authorization (PA)
    Required for many listed agents and specialty drugs; claims exceeding the dollar threshold (>= $10,000) and certain high-cost compounds (>= $75 per prescription) require PA before coverage
    Formulary codeMeaning / use
    PA
    Prior Authorization — provider must obtain approval for coverage of drugs marked PA
    QL
    Quantity Limits Apply — quantity limits established (examples shown in document)
    LDD
    Limited Distribution Drug — product may have restricted distribution channels
    AL
    Age Limit / Day supply Limit — age or day-supply restrictions may apply
    5DS
    Day Supply Limit — limits on days supplied per fill (5DS)
    R
    Requires Rider — plan-specific rider or additional requirements may apply
    Q/T
    Quantity Over Time — tracking of quantity across timeframes
    MME
    Morphine Milligram Equivalent — opioid dose safety edit (e.g., PA required > 90 MME/day)
    Product or classPAQuantity / day-supply limits
    {"text":"Amphetamine products (examples: amphetamine tablet, ER suspension)","status":""},{"text":"Yes — many amphetamine entries show PA","status":"covered"},{"text":"Some entries show QL and 5DS; cumulative stimulant dose limits apply by active ingredient (high-dose thresholds listed separately)","status":""}
    {"text":"Butalbital-containing products","status":""},{"text":"PA (butalbital/apap combinations indicated PA in listing)","status":"covered"},{"text":"QL, 5DS, and MME flags appear for some formulations","status":""}
    {"text":"Opioid products (examples: endocet, various ER opioids)","status":""},{"text":"PA indicated for some opioid formulations","status":"covered"},{"text":"MME and 5DS limits apply (opioid MME safety edit = 90 MME/day)","status":""}
    Coverage conditionExamples (documented entries)
    Prior authorization required before coverage
    Many specialty and non-preferred products in the extract are listed with REQUIREMENTS/LIMITS = PA (examples: Emgality Prefilled Pen/Auto-Injector, Epidiolex Solution, Opsynvi, Orenitram, Ormalvi Tab)
    Enforcement typeExample(s) showing code
    Prior Authorization (PA)
    Multiple drug list entries indicate REQUIREMENTS/LIMITS = PA (e.g., amphetamine entries, phentermine hcl, many topical agents) — claims may be denied without PA
    R (Requires Rider) / Day supply limits
    Some stimulant and weight-management products show R or R + PA (e.g., amphetamine entries, phentermine/topiramate) and 5DS day-supply flags
    AL (Age/Day-supply limit)
    Topical agents such as adapalene entries list AL and PA in some formulations (Adapalene pad 0.1% = PA, AL)
    Specialty agentPA required?
    {"text":"Ormalvi Tab","status":""},{"text":"Yes — listed with PA","status":"covered"}
    {"text":"Orenitram","status":""},{"text":"Yes — listed with PA","status":"covered"}
    {"text":"Opsynvi","status":""},{"text":"Listed in segment (PA indicated for many specialty agents in this section)","status":"covered"}
    Agent / classRequired codes before coverage
    {"text":"Amphetamine-class stimulants","status":""},{"text":"PA; many entries also show QL and 5DS; cumulative stimulant dose limits apply by active ingredient","status":""}
    {"text":"Butalbital and related products","status":""},{"text":"PA, QL, 5DS, MME flags present on several formulations — PA required for listed formulations","status":""}
    {"text":"Epidiolex Solution (specialty)","status":""},{"text":"PA required (entry shows PA); QL (weekly only) noted for some formulations","status":""}

    Quantity and Day-Supply Limits

    inv-95: Etonogestrel-ethinyl estradiol (Nuvaring) — quantity 1
    Limit1 ring per 28 days
    DrugEtonogestrel‑ethinyl estradiol (Nuvaring)
    ContextQuantity over time limit (30‑day/28‑day period) — override requires prior authorization
    inv-96: Ibandronate (Boniva) 150mg — quantity 1
    Limit1 tablet per 30 days
    DrugIbandronate (Boniva) 150mg
    ContextQuantity over time — override requires prior authorization
    inv-97: Sumatriptan (Imitrex) 50mg — quantity 18
    Limit18 tablets per 30 days
    DrugSumatriptan (Imitrex) 50mg
    ContextQuantity over time — override requires prior authorization
    inv-98: Diabetic test strips — quantity 200
    Limit200 strips per 30 days
    ItemDiabetic test strips
    ContextQuantity over time — most diabetic test strips require prior authorization except Contour
    inv-99: Zolpidem (Ambien) — quantity 1
    Limit1 tablet per day
    DrugZolpidem (Ambien)
    ContextMaximum daily dose quantity limit
    inv-100: Oxycodone/acetaminophen 5/325mg — quantity 12
    Limit12 tablets per day
    DrugOxycodone/acetaminophen 5/325mg
    ContextDay supply/maximum daily dose limits apply
    inv-101: Butalbital-acetaminophen 50-300mg — QL and 5DS apply
    Limit flagsQuantity Limits (QL) and Day Supply limits (5DS) apply
    DrugButalbital‑acetaminophen 50‑300mg
    ContextExamples in formulary show QL and 5DS controls for butalbital products
    inv-102: Butrans — PA, QL, MME
    Requirement flagsPA, QL, MME
    DrugButrans
    ContextOpioid safety and quantity limits applied; prior authorization required
    inv-103: Emgality Prefilled Pen/Auto-Injector 120mg/ml — QL, 5DS
    Requirement flagsQL, 5DS
    DrugEmgality Prefilled Pen/Auto-Injector 120mg/ml
    ContextQuantity and day‑supply limits noted on formulary entries
    inv-104: Various opioids (fentanyl transdermal, hydrocodone ER, hydromorphone ER) — QL, MME, 5DS
    Requirement flagsQL, MME, 5DS
    ExamplesFentanyl transdermal, hydrocodone ER, hydromorphone ER, Xodol/Norco, Xtampza ER
    ContextOpioid products commonly carry QL, MME and day‑supply limits; prior authorization may be required
    inv-105: Primlev — 5DS, MME
    Requirement flags5DS, MME
    DrugPrimlev
    ContextDay supply and MME limits apply; prior authorization indicated in entries
    inv-106: Topamax sprinkle capsules — QL, 5DS, MME
    Requirement flagsQL, 5DS, MME
    DrugTopamax sprinkle capsules
    ContextQuantity, day‑supply and MME flags shown on formulary entries
    inv-107: Xyrem — QL
    Requirement flagsQL
    DrugXyrem
    ContextQuantity limits apply; prior authorization often required
    inv-108: Praluent — QL
    Requirement flagsQL
    DrugPraluent
    ContextQuantity limits apply per formulary entry
    inv-109: Timolol maleate — PA, QL
    Requirement flagsPA, QL
    DrugTimolol maleate
    ContextPrior authorization and quantity limits noted on formulary
    inv-110: Filsuvez Gel 10% — Quantity Limits Apply
    RequirementQuantity limits apply
    DrugFilsuvez Gel 10%
    ContextFormulary entry shows QL and PA flags for some formulations

    Specialty Pharmacy and Site-of-Care

    Note

    Follow PBM Specialty Pharmacy Program requirements for specialty drugs

    Specialty drugs covered under the pharmacy benefit may be managed by the PBM's Specialty Pharmacy Program; providers should follow specialty pharmacy procedures as indicated by the PBM for dispensing and PA.

    • Specialty tier drugs often have higher cost-sharing and may be ineligible for tier exceptions.

    Policy Background

    The formulary is developed and reviewed to support safe, effective, and value-based medication use. The list includes FDA‑approved therapies and applies utilization management tools (such as prior authorization, quantity limits, and specialty pharmacy management) where appropriate. Formulary decisions, including specialty designations and tier placement, are reviewed by the Pharmacy and Therapeutics Committee to consider clinical effectiveness, safety, and value.

    Definitions & Legend

    inv-67: Formulary / Tiers definition — formulary tiers and organization
    DefinitionFormulary = list of covered medications organized by therapeutic categories and cost‑sharing tiers
    Tiers (general order)Low‑Cost Generic (LCG), Generic (G), Preferred Brand (PB), Non‑Preferred Drug (NPD), Specialty (SP)
    NotesInclusion on the formulary does not guarantee coverage; benefits vary by group
    inv-68: Prior authorization definition
    DefinitionPrior authorization is a requirement that the provider obtain approval from the health plan for coverage/payment of certain prescription drugs
    PurposeTo confirm medical necessity and appropriate use per approved criteria
    Process notePA review may take up to two business days after complete information received
    inv-69: Cumulative stimulant limit definition — calculated total daily stimulant dose by active ingredient
    DefinitionCumulative stimulant limit = calculated total daily stimulant dose by active ingredient
    PurposeSafety measure to identify high‑dose stimulant use and require provider assessment
    ConsequenceClaims exceeding per‑ingredient limits require prior authorization and may be denied at point‑of‑sale
    inv-70: Brand vs Generic formatting guidance
    GuidanceBrand‑name medications start with uppercase letter and are in bold; generics are shown in lowercase italic
    UsageThis formatting helps identify brand vs generic on the formulary
    inv-71: PA abbreviation definition
    AbbreviationPA = Prior Authorization
    ContextShown in formulary legend and drug entries to indicate requirement
    inv-72: QL abbreviation definition
    AbbreviationQL = Quantity Limits Apply
    ContextIndicates quantity limits are enforced for the drug entry
    inv-73: 5DS abbreviation definition
    Abbreviation5DS = Day Supply Limit
    ContextDenotes day‑supply limits applied to the drug (e.g., short‑acting opioids)
    inv-74: MME abbreviation definition
    AbbreviationMME = Morphine Milligram Equivalent
    ContextUsed to calculate opioid potency and safety limits (e.g., 90 MME/day)
    inv-75: NPD abbreviation definition
    AbbreviationNPD = Non Preferred Drug
    ContextTier designation used on the formulary
    inv-76: Abbreviation legend — PA / QL / SP / NPD / PB / G / LCG / MME / 5DS / LDD / AL / R
    LegendPA / QL / SP / NPD / PB / G / LCG / MME / 5DS / LDD / AL / R
    PurposeFormulary shorthand used to indicate management codes and tier assignments
    inv-77: PA (dup) definition
    DefinitionPA = Prior Authorization (legend definition)
    UsageAppears in drug entries to denote prior authorization requirement
    inv-78: QL (dup) definition
    DefinitionQL = Quantity Limits Apply (legend definition)
    UsageIndicates quantity limits for the listed product
    inv-79: SP (dup) definition
    DefinitionSP = Specialty Drug
    UsageDenotes specialty products that may be managed under specialty pharmacy
    inv-80: NPD (dup) definition
    DefinitionNPD = Non Preferred Drug
    UsageTier designation shown in formulary legend and entries
    inv-81: G (dup) definition
    DefinitionG = Generic
    UsageIndicates generic tier in formulary entries
    inv-82: Formulary shorthand / legend (dup)
    LegendFormulary shorthand / legend defines abbreviations and tier codes
    ExamplesPA, QL, SP, NPD, G, PB, LCG, LDD, AL, 5DS, MME, + = Claim Dollar Limit
    inv-83: PA (legend) definition
    DefinitionPA = Prior Authorization (legend entry)
    ContextUsed across formulary to indicate prior authorization requirement
    inv-84: QL (legend) definition
    DefinitionQL = Quantity Limits Apply (legend entry)
    ContextIndicates quantity limits on formulary entries
    inv-85: AL (legend) definition
    DefinitionAL = Day Supply Limit (legend entry)
    ContextIndicates age or day‑supply limits may apply
    inv-86: SP (legend) definition
    DefinitionSP = Specialty Drug (legend entry)
    ContextDenotes specialty products and potential specialty pharmacy management
    inv-87: NPD (legend) definition
    DefinitionNPD = Non Preferred Drug (legend entry)
    ContextIndicates non‑preferred tier assignment